In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PetroHunter Energy Corporation

http://www.petrohunter.com

Latest From PetroHunter Energy Corporation

Novo Nordisk Bets $256m On Mystery Molecule

The Danish group has licensed an unnamed product with an unknown mechanism.

Deals Companies

Chinese Oncology Startups Scoop Up VC/PE Deals In December

Oncology-focused Innovo, CytosinLab, Sino-Cell and Sinogen announced closings of early-stage funding rounds worth up to $14m. Meanwhile, Chinese developers of therapies for asthma, autoimmune skin disorders and rare diseases also raised similar new funds.

China Financing

Novo Nordisk Looks To Bring AI/ML To Cardiometabolic Disease In Valo Health Deal

Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.

Artificial Intelligence Deals

Finance Watch: Vertex Ventures, Chugai Each Raise New $200m VC Funds

Private Company Edition: Vertex Ventures (not Vertex Pharmaceuticals) closed its third fund, with $200m for life science and medical technologies, while Chugai’s $200m corporate VC fund will invest in drug discovery start-ups. Also, K36 closed a $70m series B round and Attovia launched with $60m.

Financing Innovation
See All

Company Information

UsernamePublicRestriction

Register